CILP

Summary

CILP (cartilage intermediate layer protein, HGNC:1980) is a protein-coding gene on chromosome 15q22.31, encoding Cartilage intermediate layer protein 1 (O75339). Probably plays a role in cartilage scaffolding.

Major alterations in the composition of the cartilage extracellular matrix occur in joint disease, such as osteoarthrosis. This gene encodes the cartilage intermediate layer protein (CILP), which increases in early osteoarthrosis cartilage. The encoded protein was thought to encode a protein precursor for two different proteins; an N-terminal CILP and a C-terminal homolog of NTPPHase, however, later studies identified no nucleotide pyrophosphatase phosphodiesterase (NPP) activity. The full-length and the N-terminal domain of this protein was shown to function as an IGF-1 antagonist. An allelic variant of this gene has been associated with lumbar disc disease.

Source: NCBI Gene 8483 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 241 total
• MANE Select transcript: NM_003613

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1980
Approved symbol	CILP
Name	cartilage intermediate layer protein
Location	15q22.31
Locus type	gene with protein product
Status	Approved
Aliases	HsT18872, CILP1
Ensembl gene	ENSG00000138615
Ensembl biotype	protein_coding
OMIM	603489
Entrez	8483

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 5 protein_coding

ENST00000261883, ENST00000888802, ENST00000888803, ENST00000941156, ENST00000941157

RefSeq mRNA: 1 — MANE Select: NM_003613 NM_003613

CCDS: CCDS10203

Canonical transcript exons

ENST00000261883 — 9 exons

Exon	Start	End
ENSE00000693673	65201872	65202029
ENSE00000693676	65203362	65203470
ENSE00000693679	65204268	65204582
ENSE00000693683	65205287	65205466
ENSE00000693688	65206782	65207051
ENSE00000693693	65207672	65207764
ENSE00001200864	65211428	65211473
ENSE00001200871	65209695	65209861
ENSE00001287843	65194760	65199099

Expression profiles

Bgee: expression breadth ubiquitous, 218 present calls, max score 99.27.

FANTOM5 (CAGE): breadth broad, TPM avg 2.5243 / max 214.0913, expressed in 194 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
150535	2.5243	194

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	99.27	gold quality
tendon of biceps brachii	UBERON:0008188	97.96	gold quality
tendon	UBERON:0000043	97.64	gold quality
synovial joint	UBERON:0002217	97.04	gold quality
pericardium	UBERON:0002407	94.37	gold quality
subcutaneous adipose tissue	UBERON:0002190	90.12	gold quality
skin of hip	UBERON:0001554	89.81	gold quality
diaphragm	UBERON:0001103	89.72	gold quality
gall bladder	UBERON:0002110	89.24	gold quality
decidua	UBERON:0002450	88.77	gold quality
tibia	UBERON:0000979	88.67	gold quality
layer of synovial tissue	UBERON:0007616	88.60	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	88.53	gold quality
trabecular bone tissue	UBERON:0002483	88.44	gold quality
connective tissue	UBERON:0002384	88.13	gold quality
adipose tissue	UBERON:0001013	88.09	gold quality
body of tongue	UBERON:0011876	88.06	gold quality
nipple	UBERON:0002030	87.50	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	87.43	gold quality
smooth muscle tissue	UBERON:0001135	87.30	gold quality
left uterine tube	UBERON:0001303	87.13	gold quality
triceps brachii	UBERON:0001509	87.03	gold quality
hindlimb stylopod muscle	UBERON:0004252	87.00	gold quality
olfactory bulb	UBERON:0002264	86.69	silver quality
endocervix	UBERON:0000458	86.57	gold quality
tibialis anterior	UBERON:0001385	86.54	gold quality
deltoid	UBERON:0001476	86.47	gold quality
adipose tissue of abdominal region	UBERON:0007808	86.46	gold quality
omental fat pad	UBERON:0010414	86.33	gold quality
peritoneum	UBERON:0002358	86.25	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
ACTA2	Repression
CCN2	Repression

Upstream regulators (CollecTRI, top): IGF1, SMAD3, TGFB1

miRNA regulators (miRDB)

53 targeting CILP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-302E	99.96	70.74	2669
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-520F-3P	99.82	71.32	1216
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-498-5P	99.76	69.64	1807
HSA-MIR-4465	99.71	72.56	2096
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-586	99.65	70.40	2051
HSA-MIR-4804-3P	99.65	67.78	866
HSA-MIR-5197-5P	99.64	69.08	1494
HSA-MIR-451B	99.55	68.28	1380
HSA-MIR-4687-3P	99.48	66.41	968
HSA-MIR-6083	99.47	68.73	2393
HSA-MIR-582-5P	99.47	70.79	2635
HSA-MIR-4797-5P	99.39	68.01	1354
HSA-MIR-5697	99.39	67.74	1249
HSA-MIR-542-3P	99.34	67.58	1270
HSA-MIR-3678-3P	99.31	67.10	1432
HSA-MIR-7974	99.24	65.48	1137
HSA-MIR-3125	99.14	68.49	2269
HSA-MIR-3916	98.99	68.04	2155
HSA-MIR-6859-5P	98.99	68.07	2049

Literature-anchored findings (GeneRIF, showing 11)

• CILP regulates TGF-beta signaling and that this regulation has a crucial role in the etiology and pathogenesis of LDD. (PMID:15864306)
• These observations, together with the finding that CILP protein binds and inhibits TGF-beta1, suggest that CILP and TGF-beta1 may form a functional feedback loop that controls chondrocyte metabolism. (PMID:16413503)
• SNP analysis suggested that the CILP gene is not a major risk factor for symptoms of lumbar disc disease in Finnish or Chinese populations. (PMID:17220213)
• the CILP gene 1184T/C polymorphism is a significant risk factor for lumbar disc degeneration occurrence in Japanese collegiate judo athletes (PMID:19569011)
• The researchers found that the single nucleotide polymorphism (1184T/C) of the CILP gene is associated an increased risk of lumbar disc degeneration in male athletes. (PMID:20724643)
• CILP is involved in the etiology of intervertebral disc degeneration among young adults. (PMID:22107760)
• Meta-analysis. Our results confirm the positive association between CILP and intervertebral disc degeneration, providing novel clues for clarifying the role of CILP in the development of IVD. (PMID:27359356)
• CILP rs2073711 TT is associated with increased risk of symmetrical hand osteoarthritis particularly in individuals with low variation in work tasks. (PMID:29233086)
• CILP gene polymorphism (rs2073711) is associated with a lower risk of lumbar disc degeneration. (PMID:30288688)
• CILP is a potential pan-cancer marker: combined silico study and in vitro analyses. (PMID:37968343)
• CILP-1 Is a Biomarker for Backward Failure and Right Ventricular Dysfunction in HFrEF. (PMID:38132152)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cilp	ENSDARG00000053362
mus_musculus	Cilp	ENSMUSG00000042254
rattus_norvegicus	Cilp	ENSRNOG00000029911

Paralogs (1): CILP2 (ENSG00000160161)

Protein

Protein identifiers

Cartilage intermediate layer protein 1 — O75339 (reviewed: O75339)

Alternative names: Cartilage intermediate-layer protein

All UniProt accessions (1): O75339

UniProt curated annotations — full annotation on UniProt →

Function. Probably plays a role in cartilage scaffolding. May act by antagonizing TGF-beta1 (TGFB1) and IGF1 functions. Has the ability to suppress IGF1-induced proliferation and sulfated proteoglycan synthesis, and inhibits ligand-induced IGF1R autophosphorylation. May inhibit TGFB1-mediated induction of cartilage matrix genes via its interaction with TGFB1. Overexpression may lead to impair chondrocyte growth and matrix repair and indirectly promote inorganic pyrophosphate (PPi) supersaturation in aging and osteoarthritis cartilage.

Subunit / interactions. Monomer. Interacts with TGFB1.

Subcellular location. Secreted. Extracellular space. Extracellular matrix.

Tissue specificity. Specifically expressed in cartilage. Localizes in the intermediates layer of articular cartilage but neither in the superficial nor in the deepest regions. Specifically and highly expressed in intervertebral disk tissue. Expression increases with aging in hip articular cartilage. Overexpressed in articular hyaline cartilage from patients with calcium pyrophosphate dihydrate crystal deposition disease (CPPD). Expression in intervertebral disk tissue from individuals with lumbar disk disease increases as disk degeneration progresses.

Post-translational modifications. Cleaved into 2 chains possibly by a furin-like protease upon or preceding secretion.

Disease relevance. Intervertebral disc disease (IDD) [MIM:603932] A common musculo-skeletal disorder caused by degeneration of intervertebral disks of the lumbar spine. It results in low-back pain and unilateral leg pain. Disease susceptibility is associated with variants affecting the gene represented in this entry.

Miscellaneous. Antibodies against CILP are detected in patients with early-stage knee osteoarthritis and rheumatoid arthritis.

RefSeq proteins (1): NP_003604* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000884	TSP1_rpt	Repeat
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR008969	CarboxyPept-like_regulatory	Homologous_superfamily
IPR013783	Ig-like_fold	Homologous_superfamily
IPR025155	WxxW_domain	Domain
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR036383	TSP1_rpt_sf	Homologous_superfamily
IPR039675	CILP1/CILP2	Family
IPR056255	CILP-1/2_dom	Domain
IPR056256	CILP-1/2_b-sand_dom2	Domain
IPR056257	CILP-1/2_8th	Domain
IPR056258	CILP-1/2_C	Domain

Pfam: PF00090, PF13330, PF13927, PF23591, PF23599, PF23708, PF23730

UniProt features (35 total): sequence variant 11, glycosylation site 8, disulfide bond 4, sequence conflict 4, chain 3, domain 2, signal peptide 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75339-F1	80.30	0.35

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (4): 161–195, 165–200, 177–185, 330–376

Glycosylation sites (8): 346, 420, 550, 631, 1000, 1056, 129, 132

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)

MSigDB gene sets: 118 (showing top): GOBP_SMAD_PROTEIN_SIGNAL_TRANSDUCTION, TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_UP, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, MODULE_64, SMID_BREAST_CANCER_RELAPSE_IN_LUNG_DN, CAGCTG_AP4_Q5, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_INSULIN_LIKE_GROWTH_FACTOR_RECEPTOR_SIGNALING_PATHWAY, GOBP_REGULATION_OF_TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_SIGNALING_PATHWAY, GOBP_RESPONSE_TO_TRANSFORMING_GROWTH_FACTOR_BETA, GOMF_EXTRACELLULAR_MATRIX_STRUCTURAL_CONSTITUENT, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_TRANSFORMING_GROWTH_FACTOR_BETA_STIMULUS, GOBP_RESPONSE_TO_GROWTH_FACTOR, GOBP_REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_RECEPTOR_SIGNALING_PATHWAY, GOBP_TRANSFORMING_GROWTH_FACTOR_BETA_RECEPTOR_SIGNALING_PATHWAY

GO Biological Process (4): negative regulation of gene expression (GO:0010629), negative regulation of transforming growth factor beta receptor signaling pathway (GO:0030512), negative regulation of insulin-like growth factor receptor signaling pathway (GO:0043569), negative regulation of SMAD protein signal transduction (GO:0060392)

GO Molecular Function (1): extracellular matrix structural constituent (GO:0005201)

GO Cellular Component (4): obsolete extracellular space (GO:0005615), extracellular matrix (GO:0031012), extracellular exosome (GO:0070062), extracellular region (GO:0005576)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Signaling by Receptor Tyrosine Kinases	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	2
gene expression	1
regulation of gene expression	1
negative regulation of macromolecule biosynthetic process	1
transforming growth factor beta receptor signaling pathway	1
regulation of transforming growth factor beta receptor signaling pathway	1
negative regulation of signal transduction	1
regulation of insulin-like growth factor receptor signaling pathway	1
insulin-like growth factor receptor signaling pathway	1
regulation of SMAD protein signal transduction	1
SMAD protein signal transduction	1
negative regulation of intracellular signal transduction	1
structural molecule activity	1
extracellular matrix	1
external encapsulating structure	1
extracellular vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

956 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CILP	ASPN	Q9BXN1	843
CILP	COL9A3	Q14050	819
CILP	COL9A2	Q14055	803
CILP	COL11A1	P12107	755
CILP	THBS2	P35442	646
CILP	FURIN	P09958	611
CILP	LUM	P51884	566
CILP	PRELP	P51888	559
CILP	ACAN	P16112	548
CILP	COMP	P49747	524
CILP	CHAD	O15335	517
CILP	PRG4	Q92954	502
CILP	FMOD	Q06828	493
CILP	FN1	P02751	487
CILP	HAPLN1	P10915	469

IntAct

5 interactions, top by confidence:

A	B	Type	Score
TGFB1	CILP	psi-mi:“MI:0914”(association)	0.430
CILP	TGFB1	psi-mi:“MI:0403”(colocalization)	0.430
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350
ATG16L1		psi-mi:“MI:0914”(association)	0.350

BioGRID (4): ERH (Cross-Linking-MS (XL-MS)), CILP (Affinity Capture-MS), CILP (Affinity Capture-MS), CILP (Affinity Capture-MS)

ESM2 similar proteins: A0A8M9PFP2, A1L2K1, A4IGL3, A4IH88, A8WFR0, B0S5G3, F1LW30, L7VG99, O42146, O73746, O75339, O93449, O97591, P12032, P15203, P16035, P16176, P16368, P20614, P23667, P25785, P26652, P30120, P30121, P30970, P35625, P39876, P48032, P61269, P79121, Q01H84, Q09199, Q28GB8, Q3KTM2, Q5PXZ9, Q60453, Q66K08, Q6DDG2, Q6UXZ4, Q7ZV46

Diamond homologs: D3Z7H8, O15394, O19112, O35136, O75339, P20241, P70193, P98167, Q66K08, Q6PDN3, Q8IUL8, Q8WZ42, A4IGL7, G5ECS8, P35440, Q2TBA3, Q7TQM3, Q91V87, Q92626, Q96JA1, Q9UDY8, A2ASS6, D3YXG0, P17948, Q15746, Q2EY14, Q2EY15, Q2VWP7, Q2VWP9, Q3UH53, Q589G5, Q58EX2, Q6UWL6, Q6V4S5, Q7Z5N4, Q8AV57, Q8BQC3, Q8IVU1, Q96RW7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

241 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	216
Likely benign	14
Benign	6

Top pathogenic / likely-pathogenic (0)

SpliceAI

1393 predictions. Top by Δscore:

Variant	Effect	Δscore
15:65201866:GCTTA:G	donor_loss	1.0000
15:65201867:CTTAC:C	donor_loss	1.0000
15:65201869:TAC:T	donor_loss	1.0000
15:65201870:A:AC	donor_gain	1.0000
15:65201870:A:C	donor_loss	1.0000
15:65201871:C:CC	donor_gain	1.0000
15:65201871:C:T	donor_loss	1.0000
15:65202027:TAC:T	acceptor_gain	1.0000
15:65202030:C:CC	acceptor_gain	1.0000
15:65202030:CTGC:C	acceptor_loss	1.0000
15:65202031:T:A	acceptor_loss	1.0000
15:65207670:A:AC	donor_gain	1.0000
15:65207670:ACTCT:A	donor_gain	1.0000
15:65207671:C:CC	donor_gain	1.0000
15:65207671:CT:C	donor_gain	1.0000
15:65207671:CTCT:C	donor_gain	1.0000
15:65207671:CTCTC:C	donor_gain	1.0000
15:65207674:T:A	donor_gain	1.0000
15:65207761:CTCC:C	acceptor_gain	1.0000
15:65207763:CC:C	acceptor_gain	1.0000
15:65207763:CCCT:C	acceptor_loss	1.0000
15:65207764:CC:C	acceptor_gain	1.0000
15:65207764:CCTG:C	acceptor_loss	1.0000
15:65207765:C:CC	acceptor_gain	1.0000
15:65207766:T:A	acceptor_loss	1.0000
15:65209712:T:TA	donor_gain	1.0000
15:65199100:C:CC	acceptor_gain	0.9900
15:65201870:AC:A	donor_gain	0.9900
15:65201871:CC:C	donor_gain	0.9900
15:65201871:CCT:C	donor_gain	0.9900

AlphaMissense

7814 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:65197001:G:C	C1095W	0.999
15:65197003:A:G	C1095R	0.999
15:65197002:C:G	C1095S	0.998
15:65197003:A:T	C1095S	0.998
15:65197257:C:G	C1010S	0.998
15:65197258:A:G	C1010R	0.998
15:65197258:A:T	C1010S	0.998
15:65197424:G:C	C954W	0.998
15:65197425:C:T	C954Y	0.998
15:65197426:A:G	C954R	0.998
15:65197454:C:A	W944C	0.998
15:65197454:C:G	W944C	0.998
15:65197002:C:T	C1095Y	0.997
15:65197256:G:C	C1010W	0.997
15:65197271:A:C	C1005W	0.997
15:65197273:A:G	C1005R	0.997
15:65197451:C:A	W945C	0.997
15:65197451:C:G	W945C	0.997
15:65197456:A:G	W944R	0.997
15:65197456:A:T	W944R	0.997
15:65197002:C:A	C1095F	0.996
15:65197057:A:C	Y1077D	0.996
15:65197189:A:G	C1033R	0.996
15:65197257:C:T	C1010Y	0.996
15:65197310:G:C	S992R	0.996
15:65197310:G:T	S992R	0.996
15:65197312:T:G	S992R	0.996
15:65197425:C:A	C954F	0.996
15:65198164:A:G	W708R	0.996
15:65198164:A:T	W708R	0.996

dbSNP variants (sampled 300 via entrez): RS1000004789 (15:65206722 C>G,T), RS1000037823 (15:65196134 G>C), RS1000104363 (15:65194792 A>G), RS1000214808 (15:65212014 C>T), RS1000410232 (15:65196537 G>A), RS1000656709 (15:65201400 G>A), RS1000880630 (15:65201651 C>T), RS1000890024 (15:65195686 C>G), RS1000975125 (15:65202091 G>A), RS1001127455 (15:65207611 C>A,T), RS1001490829 (15:65207371 A>C,G,T), RS1001520853 (15:65212688 C>T), RS1001541937 (15:65203132 C>A,G,T), RS1001656579 (15:65202831 C>A,G,T), RS1001727479 (15:65208973 A>G)

Disease associations

OMIM: gene MIM:603489 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST010796_4774	Electrocardiogram morphology (amplitude at temporal datapoints)	5.000000e-11
GCST010796_4775	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-09
GCST010796_4776	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-09
GCST010796_4777	Electrocardiogram morphology (amplitude at temporal datapoints)	5.000000e-09
GCST010796_4778	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004327	electrocardiography

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression, affects cotreatment	2
Dexamethasone	increases expression, affects cotreatment	2
Estradiol	affects cotreatment, increases expression	2
Nickel	decreases expression	2
Genistein	increases expression	2
methylmercuric chloride	increases expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
sodium arsenite	increases expression	1
perfluorooctanoic acid	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
perfluorooctane sulfonic acid	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Acetaminophen	increases expression	1
Calcitriol	increases expression	1
Cisplatin	affects response to substance	1
Copper	affects binding, decreases expression	1
Diethylstilbestrol	increases expression	1
Disulfiram	affects binding, decreases expression	1
Doxorubicin	decreases expression	1
Indomethacin	affects cotreatment, increases expression	1
Lipopolysaccharides	affects response to substance, increases expression	1
Plant Extracts	decreases expression, affects cotreatment	1
Progesterone	increases expression, affects cotreatment	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases methylation	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Aflatoxin B1	increases methylation	1
Medroxyprogesterone Acetate	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.